Showing posts with label ProAir RespiClick (albuterol sulfate) Inhalation Powder. Show all posts
Showing posts with label ProAir RespiClick (albuterol sulfate) Inhalation Powder. Show all posts

Tuesday, January 3, 2017

Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11

Teva Pharmaceutical Industries Ltd.,  announced  that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in children 4 to 11 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).


Salbutamol.svg



ProAir RespiClick was approved by the FDA for use in patients 12 years of age and older in March 2015 and remains the only breath-activated, multi-dose, dry powder, short-acting beta-agonist (SABA) inhaler available in the U.S.